We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Friday that the EU drug regulator's Committee for Medicinal Products for Human Use has recommended marketing authorization for Bevespi Aerosphere, an inhaler for treatment of chronic obstructive pulmonary disease.
The recommendation from the European Medicines Agency committee is based on the company's phase 3 pinnacle program, which demonstrated the efficacy and safety of the inhaler, the pharmaceutical company said.
Bevespi Aerosphere is approved in the U.S., Canada and Australia as a dual bronchodilator for the long-term maintenance treatment of chronic obstructive pulmonary disease, AstraZeneca said.
Shares at 1216 GMT were up 0.8% at 5,927 pence.
Write to Adria Calatayud at adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
October 19, 2018 08:36 ET (12:36 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
